Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis

• Published in: Oncotarget Vol. 8; no. 35; pp. 59570 - 59580
• Main Authors: Zhu, Zhenhua, Jin, Zheng, Zhang, Mei, Tang, Yajun, Yang, Guang, Yuan, Xiaowei, Yao, Jihang, Sun, Dahui
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 29.08.2017
• Subjects: Meta-Analysis; meta-analysis; programmed death-ligand 1; sarcoma; prognosis; survival
• DOI: 10.18632/oncotarget.19168
• ISSN: 1949-2553

The prognostic role of programmed death-ligand 1 (PD-L1) in sarcoma remains controversial. We performed a meta-analysis so as to investigate the impact of PD-L1 on clinicopathlogical findings and survival outcomes in sarcoma. A comprehensive search in PubMed, Embase and the Cochrane Library was conducted for relevant studies. The odds ratios or hazard ratios, at 95% confidence intervals were used as measures for investigation of the correlation between PD-L1 expression and clinicopathlogical features or survival outcomes. Fourteen eligible studies comprising 868 patients were selected for analysis. Pooled hazard ratios indicated that the association of PD-L1 expression with overall survival in bone sarcoma (osteosarcoma and chondrosarcoma) patients was statistically significant (1.987, 95% CI: 1.224-3.224, = 0.005), as was its association with event-free survival in bone and soft-tissue sarcoma patients (3.868, 95% CI: 2.298-6.511, = 0.000). Additionally, the expression of PD-L1 was positively correlated with the infiltration of programmed death 1 (PD-1) positive T-lymphocytes (OR: 4.012, 95% CI: 2.391-6.733, = 0.000). Our meta-analysis indicated that high PD-L1 expression is likely to be a negative factor for patients with sarcomas and that it predicts worse survival outcomes.